Menu

Trial Launched to Treat Parkinson’s with Reprogrammed Stem Cells

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Jul 31, 2018
Diana Kwon

On Monday (July 30), researchers at Kyoto University in Japan announced that they were launching a clinical trial to treat Parkinson’s disease using reprogrammed adult stem cells. 

“This will be the world’s first clinical trial using [induced pluripotent stem] cells on Parkinson’s disease,” Jun Takahashi, a neurosurgeon at Kyoto University’s Centre for iPS Cell Research and Application, told reporters (via Reuters). 

Takahashi and his colleagues will inject dopamine-producing neural progenitor cells—derived from induced pluripotent stem cells (iPSCs) from healthy adult donors—into Parkinson’s patients’ brains. Approximately 5 million cells will be injected into the patients’ striatum (in red above), the primary brain region implicated in the disease. 

The team plans to recruit seven participants and to observe each patient for two years after the injection. 

Last year, Takahashi and his colleagues reported that the injected cells could survive in monkey brains for up to two years, and that the treatment improved symptoms in a primate model of Parkinson’s disease.

See “Parkinson’s Disease Cell Therapy Relieves Symptoms in Monkeys

According to Science, this is the third iPSC clinical trial approved in Japan. The other two are aimed at treating age-related macular degeneration and heart disease.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Immunophenotypic Analysis of Human Blood Leukocyte Subsets

Download this application note from ACEA Biosciences, Inc., to find out how to perform an immunophenotypic analysis of a human blood sample utilizing 13 fluorescent markers using a compact benchtop flow cytometer equipped with 3 lasers!

Choosing the Right Filtration Solutions to Complete Your Laboratory

Choosing the Right Filtration Solutions to Complete Your Laboratory

Ductless fume hoods, laminar flow hoods, and biological safety cabinets are all designed to meet the needs of highly specific, yet extremely diverse situations. Find out which hood is right for you with this guide from Air Science!